These data suggest that MET amplification/activation and EGFR C797X secondary mutation, which are commonly associated with acquired resistance to osimertinib in post-progression tumor in human patients, were unlikely the primary mechanism of osimertinib tolerance at the early stage of osimertinib treatment. The gene discussed is MET; the disease is neoplasm.